

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**MicroPort NeuroScientific Corporation**

**微創腦科學有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2172)**

## **CHANGE OF NON-EXECUTIVE DIRECTORS AND CHAIRMAN OF THE BOARD**

This announcement is made by MicroPort NeuroScientific Corporation (the “**Company**”) pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company announces the following changes to the Board with effect from November 14, 2025:

### **Resignation of non-executive Directors and the chairman of the Board**

Dr. Chang Zhaohua (“**Dr. Chang**”) has resigned as non-executive Director and chairman of the Board due to the need to devote more time to other business endeavours. Mr. Sun Qingwei (“**Mr. Sun**”) has resigned as non-executive Director due to the need to devote more time to other business endeavours. Dr. Chang and Mr. Sun have confirmed to the Company that they have no disagreement with the Board. The Company confirms that there is no matter relating to the resignations of Dr. Chang and Mr. Sun that needs to be brought to the attention of the shareholders of the Company. The Company would like to express its sincere gratitude to Dr. Chang and Mr. Sun for their dedicated efforts and valuable contributions to the Group during their respective terms as non-executive Directors, and looks forward to their continued professional guidance, suggestions and advice for the development of the Group in the future.

### **Appointment of non-executive Directors and the chairman of the Board**

Dr. Zhang Jie (張劼) (“**Dr. Zhang**”) has been appointed as a non-executive Director and the chairman of the Board.

Dr. Zhang, born in 1979, is a member of Greater China Executive Committee (“CEC”) and Chief Technology Officer of CEC of MicroPort Scientific Corporation (“MicroPort”, a company listed on the Hong Kong Stock Exchange, stock code: 853). As an Outstanding Technical Leader in Shanghai, he also provides in-house mentorship for postgraduates at Zhejiang University, East China University of Science and Technology and University of Shanghai for Science and Technology. Dr. Zhang joined MicroPort in 2007. As the principal researcher and key inventor of technologies for the Firehawk® Stent, Dr. Zhang effectively overcame complex technological challenges and secured several invention patents both domestically and internationally. Since joining MicroPort, Dr. Zhang has played a crucial role in the development of new technologies and products. He has spearheaded R&D efforts across multiple businesses within MicroPort, while incubating emerging products in the areas of ophthalmology, otorhinolaryngology, dentistry and medical cosmetology. Dr. Zhang has amassed multiple innovations over the past 17 years, secured the First Prize of the Shanghai Scientific and Technological Progress Awards and the Silver Prize of the China Patent Award, and now has 53 domestic and international authorized patents.

Dr. Zhang received his bachelor’s degree in communication engineering from Zhejiang University of Technology in 2002, his master’s degree in Test and Measurement Technology and Instrumentation in 2007, and his Ph.D. in Biomedical Engineering in 2021, both from University of Shanghai for Science and Technology.

Dr. Zhang is interested in 136,447 shares of MicroPort and 1,400,913 underlying shares of MicroPort by virtue of options. He is further interested in 33,145 shares of the Company, and 200,000 underlying shares of MicroPort CardioFlow Medtech Corporation (a company listed on the Hong Kong Stock Exchange, stock code: 2160) by virtue of options, all within the meaning of Part XV of the Securities and Futures Ordinance (the “SFO”).

Mr. Liu Xudong (劉旭東) (“Mr. Liu”) has been appointed as a non-executive Director.

Mr. Liu, born in 1975, is the executive deputy general manager of Shanghai MicroPort Weilian Weitong Health Management Co., Ltd.\* (上海微創微聯微通健康管理有限公司).

Mr. Liu has nearly 25 years of marketing experience in the healthcare sector and more than 15 years of experience managing marketing teams. From 2005 to 2023, Mr. Liu worked at Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (a company listed on the Shenzhen Stock Exchange, stock code: 300760.SZ, “Mindray”), primarily responsible for sales and successively served as regional manager, senior regional manager and department head. In 2024, Mr. Liu worked at Shanghai BioGerm Medical Technology Co., Ltd. as deputy general manager of marketing, where he assumed overall responsibility for the sales, marketing, technical support and commercial departments, and led the upgrade of the sales system and reconstruction of the distribution channels.

Mr. Liu received his bachelor's degree in marketing from Shandong University in 2005, and MBA degree from Capital University of Economics and Business in 2008.

As at the Latest Practicable Date, Mr. Liu was not interested or deemed to be interested in shares, underlying shares or debentures of the Company or its associated corporation pursuant to Part XV of the SFO.

Save as disclosed above, Dr. Zhang and Mr. Liu has not held any directorship in other listed public companies in Hong Kong or overseas in the last three years, and they are not related to any Directors, senior management, other substantial or controlling shareholders (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")) of the Company, nor do they hold any other positions with the Company or any of its subsidiaries.

Dr. Zhang and Mr. Liu will enter into a letter of appointment with the Company, subject to rotation and re-election at annual general meetings in accordance with the Articles of Association of the Company. Dr. Zhang and Mr. Liu will not receive any emolument for serving as a non-executive Director.

There is no information which is discloseable nor are Dr. Zhang and Mr. Liu involved in any of the matters required to be disclosed pursuant to any of the requirements under Rules 13.51(2)(h) to (v) of the Listing Rules and there are no other matters concerning the appointment of Dr. Zhang and Mr. Liu that need to be brought to the attention of the shareholders of the Company.

The Board hereby expresses its warmest welcome to Dr. Zhang and Mr. Liu for their new appointments.

By order of the Board  
**MicroPort NeuroScientific Corporation**  
**Dr. Zhang Jie**  
*Chairman and Non-executive Director*

Hong Kong, November 14, 2025

*As at the date of this announcement, the Board comprises Mr. Xie Zhiyong and Mr. Wang Yiqun Bruce as the executive directors; Dr. Zhang Jie, Mr. Liu Xudong and Ms. Wu Xia as the non-executive directors; and Dr. Zhang Haixiao, Mr. Fan Xin and Mr. Li Zhiyong as the independent non-executive directors.*